Currently viewing the tag: "pharmaceuticals"

On September 3, Swiss-based pharmaceutical giant Novartis launched the first American “biosimilar”—a copycat version of a complex biologic drug.  Novartis is offering it’s product Zarxio at a wholesale price that is 15% less than the wholesale price of the product it mimics: […]

Continue Reading

The Supreme Court Takes on Big Pharma

On April 6, 2011 By

In a number of recent cases, the Supreme Court has taken on the pharmaceutical industry, resulting in decisions with important implications for plaintiffs, drug manufacturers, and Americans who purchase pharmaceutical drugs.

On February 22, the Court held in Bruesewitz et al. v. Wyeth Inc. that the National Childhood Vaccine Injury Act of 1986, […]

Continue Reading

Monday Morning JetLawg

On February 7, 2010 By

In the news . . .

Google and NSA team up to fight cyberattacks.

Scientists discover energy teleportation.

Seventh Circuit upholds prison ban on Dungeons & Dragons against First and Fourteenth Amendment challenge.

Australian copyright holders lose ability to compel ISP assistance. Meanwhile, new Aussie […]

Continue Reading

The Cost of Kickbacks

On January 26, 2010 By

To the drug companies that are awarding kickbacks for prescribing or otherwise recommending their drugs, I have two words: stop it!

I respect the time, effort, and money that pharmaceutical companies devote to drug research and development, and advertising the drugs that are ultimately developed is an inevitable part of the research and development […]

Continue Reading

Biosimilar Bills Foment Heated Debate

On July 23, 2009 By

Most people agree that a generic biologics pathway for the U.S. Food and Drug Administration (FDA) approval of these drugs would be a boon to consumers, but different parties seem to be at odds on the exact exclusivity period that the pharmaceutical companies should be given from their generic drug competitors.

These generic biologics […]

Continue Reading

Goat Milk for Health

On February 15, 2009 By

Sometimes it’s hard to have a lot of faith in the FDA– especially in light of recent reports that the Georgia peanut plant at the heart of salmonella-related deaths was home to roaches and other goodies. Well, last week the FDA approved the use of dairy goats by drug manufacturers. The goats […]

Continue Reading

Pfizer, Inc., the world’s largest research-based pharmaceutical company, announced on October 1 that it plans to discontinue research and development in the areas of heart disease, cholesterol, obesity and bone health. The company predicated its decision on the scheduled 2011 expiration of the company’s patent for its bestselling, cholesterol-reducing drug, Lipitor. Research and […]

Continue Reading